R - Elevance Health: The Multi-Year Re-Rating Opportunity

Elevance is framed as a trough-year story, with 2026 EPS guidance of at least $25.50 versus a normalized 2025 base of about $26.54 after stripping $3.75 of one-time benefits. The bullish case hinges on Carelon margin expansion from 4.8% to 6.5%, which could add roughly $4.33 per share, while broader enterprise margin improvement could contribute another ~$7.11 per share. At about 13x forward earnings, the stock looks priced for the trough rather than the recovery, with institutional buyers still accumulating positions.

Analysis

The market is treating ELV like a clean earnings reset, but the more important second-order effect is that 2026 likely becomes the year the company de-risks its book while competitors still fight bad acuity normalization. That can create a valuation floor: when a payer exits low-quality Medicare Advantage geographies and absorbs Medicaid margin compression at once, headline EPS looks worse, but the remaining mix is usually more durable and less capital-destructive. In other words, the trough may actually improve the quality of future comp growth rather than simply delay it.

The real upside is operating leverage inside Carelon, which is underappreciated because investors tend to anchor on revenue scale rather than margin conversion. If the services platform closes even part of the gap to peer economics, the incremental EPS contribution is large enough to change the multiple, not just justify it. That makes ELV less of a defensive healthcare name and more of a self-help compounder whose rerating could come in 2 stages: first on visible 2026 stabilization, then on proof points that CarelonRx/Carelon Services are moving toward better returns on capital.

The consensus miss is likely the timing. The stock does not need a flawless 2026; it needs signs that 2027 exits the trough with margin expansion intact. If utilization or Medicaid pressure worsens, downside is mostly a one-year earnings air pocket, but if operating leverage shows up, the market could quickly stop valuing ELV on trough EPS and start using a normalized mid-teens earnings power number. That is why the setup is asymmetrical: limited multiple compression from here unless the thesis breaks, but meaningful rerating if management delivers even partial execution.

Relative winners are likely the diversified insurers with embedded services platforms and disciplined capital allocation, while pure-play payers without comparable margin engines may lag as investors prefer self-help over stable but lower-growth models. UNH is the closest natural comparator if the market decides to pay up for integrated healthcare economics again; CI can participate, but with less direct evidence of a similar scale/services bridge. The main external risk is not competitive pressure from other managed care names, but a macro/regulatory squeeze that delays the margin reset long enough to keep the stock trapped in a low-multiple range for several quarters.

Key Decisions for Investors

• Long ELV on weakness over the next 2-6 weeks; use the 2026 trough narrative as entry, with a 6-12 month horizon and upside tied to rerating toward normalized EPS power.
• Pair trade: long ELV / short a basket of lower-quality managed care exposure without an obvious services margin bridge; this expresses relative self-help vs. stagnant operating leverage over 3-9 months.
• Buy ELV call spreads 6-9 months out to capture the rerating if Carelon margin progress shows up before the market fully discounts 2027 earnings power; define risk tightly via premium paid.
• If you want a cleaner quality-vs-growth expression, long ELV and short CI as a relative-value trade into earnings season, betting that the market rewards clearer margin bridge visibility.
• Trim or hedge if management commentary suggests the 2027 margin bridge is slipping; the thesis is execution-sensitive, and the stock can stay rangebound if the market keeps anchoring on trough EPS.